Targeting Fructose Metabolism in Cancer: The Polyol Pathway Link

Study Background and Research Question

Fructose, often perceived as a benign dietary sugar, has come under scrutiny for its role in cancer progression. Zhao et al. (2025) synthesize emerging evidence that fructose metabolism is not merely a metabolic alternative but a driver of malignancy in several aggressive cancers (Zhao et al., 2025). The research question central to this review is whether enzymes and transporters responsible for fructose catabolism—particularly those within the polyol pathway—can be targeted to disrupt tumor bioenergetics and signaling, thereby offering new avenues for cancer therapy.

Key Innovation from the Reference Study

The review's primary innovation lies in drawing a robust mechanistic and epidemiological link between fructose metabolism and cancer severity. Notably, it emphasizes the polyol pathway as a source of endogenous fructose production within tumor cells. In this pathway, glucose is reduced to sorbitol by aldose reductase (AKR1B1), and then sorbitol is oxidized to fructose by sorbitol dehydrogenase (SORD). This endogenous pathway becomes particularly relevant in the tumor microenvironment, where glucose scarcity may drive reliance on fructose as an alternative substrate (Zhao et al., 2025). By integrating recent transcriptomic and mortality-to-incidence ratio (MIR) data, Zhao et al. highlight that highly malignant cancers (e.g., hepatocellular carcinoma, pancreatic cancer, lung cancer) exhibit upregulation of fructose transporters (GLUT5) and polyol pathway enzymes (AKR1B1). This upregulation correlates with poor prognosis and aggressive disease phenotypes, positioning the pathway as a strategic therapeutic target.

Methods and Experimental Design Insights

As a review article, Zhao et al. aggregate molecular, clinical, and epidemiological studies. Their approach includes:

• Comparative expression analyses of key fructose pathway genes (GLUT5, KHK, AKR1B1) in tumor versus normal tissues.
• Analysis of dietary fructose intake studies and their correlation with cancer incidence and progression.
• Meta-analysis of global cancer datasets (top 20 by incidence) and calculation of mortality-to-incidence ratio (MIR) to prioritize cancers with the highest clinical burden linked to fructose metabolism.

A mechanistic focus is placed on the polyol pathway's role in sustaining tumor growth under metabolic stress. References to preclinical models where inhibition of fructose metabolism impairs tumor growth supplement the epidemiological findings (Zhao et al., 2025).

Protocol Parameters

• cell viability assay | 1–10 μM Epalrestat | cancer and neurodegeneration models | Range supported for AKR1B1 inhibition without generalized toxicity; modulates polyol pathway activity | workflow_recommendation
• cytotoxicity assay | 3–10 μM Epalrestat | metabolic stress or oxidative damage assays | Validated for evaluating protective or sensitizing effects during polyol pathway blockade | workflow_recommendation
• DMSO solubility | ≥6.375 mg/mL | stock solution prep for in vitro use | Ensures accurate dosing in cell-based studies; avoids precipitation | product_spec
• assay temperature | 37°C | standard for mammalian cell culture | Maintains physiological relevance and enzyme activity | workflow_recommendation
• storage | -20°C (solid) | long-term compound stability | Prevents degradation and maintains batch consistency | product_spec

Core Findings and Why They Matter

Zhao et al. report that cancers with high MIRs—specifically hepatocellular carcinoma, pancreatic, and lung cancers—show marked upregulation of fructose transporters (GLUT5) and polyol pathway enzymes (AKR1B1). This metabolic reprogramming enables cancer cells to:

• Utilize fructose as an alternative energy substrate, particularly under glucose-limited conditions (the Warburg effect).
• Activate oncogenic signaling (e.g., mTORC1), supporting proliferation, angiogenesis, and metastasis.
• Suppress anti-tumor immune responses, contributing to immune evasion.

The review underscores that targeting fructose metabolism—through inhibition of transporters or key enzymes such as AKR1B1—may restrict tumor growth and improve therapeutic outcomes (Zhao et al., 2025).

Comparison with Existing Internal Articles

Recent internal literature has explored the application of aldose reductase inhibitors, particularly Epalrestat, in metabolic and neurodegenerative disease models. For example, articles such as "Epalrestat: Mechanistic Insights and Research Utility" and "Epalrestat (SKU B1743): Practical Solutions for Cell Viability" discuss the use of Epalrestat in inhibiting the polyol pathway to reduce sorbitol accumulation and oxidative stress in diabetic complications (internal_article; internal_article). These findings align with Zhao et al.'s focus on the polyol pathway as a driver of disease, but extend the relevance from metabolic and neurodegenerative disorders to oncology. Moreover, internal resources have documented Epalrestat's role in neuroprotection via KEAP1/Nrf2 pathway activation, a mechanism potentially relevant for counteracting oxidative stress in cancer cells (internal_article). This cross-domain mechanistic insight suggests a broader utility of polyol pathway inhibitors in both metabolic and proliferative diseases.

Limitations and Transferability

While Zhao et al. present compelling associations, the review's reliance on aggregated data means that direct causality and therapeutic efficacy in clinical oncology remain to be established. Most functional evidence comes from in vitro or preclinical models; translation to patient outcomes requires further investigation. Additionally, the broad metabolic roles of the polyol pathway in non-cancer tissues raise concerns about potential systemic side effects of pathway inhibition (Zhao et al., 2025). A further limitation is the complexity of metabolic reprogramming in tumors, which may develop compensatory pathways upon targeted intervention. Thus, the review advocates for combined treatment strategies, including the integration of polyol pathway inhibitors with established therapies, to minimize resistance and maximize efficacy.

Why this cross-domain matters, maturity, and limitations

The cross-domain applicability of aldose reductase inhibition—extensively studied in diabetic neuropathy and neurodegeneration—to oncology is conceptually supported by shared underlying mechanisms: polyol pathway upregulation, oxidative stress, and metabolic adaptation. However, while preclinical models and metabolic assays offer proof of principle, clinical translation in cancer remains at an early stage, necessitating further validation in tumor-specific systems (Zhao et al., 2025).

Research Support Resources

For researchers aiming to interrogate the polyol pathway in cancer or metabolic models, high-purity aldose reductase inhibitors such as Epalrestat (SKU B1743) are available. Epalrestat is validated for reliable inhibition of AKR1B1 activity and is DMSO-soluble at concentrations suitable for in vitro workflows (product_spec). As highlighted in internal best-practice articles (internal_article), careful consideration of solubility, dosing, and storage is essential for reproducibility. APExBIO offers Epalrestat with stringent quality control for research use only—not for clinical application.